The People’s Bank of China (PBoC) has cut the reserve requirement ratio (RRR) for most banks by 100bps, effective from October 15. According to the official press release, the cut will release a total of CNY1.2 trillion into the banking system. The RRR cut will engineer a credit impulse into the economy, representing an upside risk to growth, according to the latest report from ANZ Research.
The RRR cut is a target one which aims to replace the PBoC’s medium-term lending facility (MLF) of CNY450 billion. Therefore, the action will still result in a net injection of CNY750 billion. The PBoC also reiterated that China’s M2 money supply growth will be kept stable and the RRR cut will not fuel depreciation pressure on the yuan’s exchange rate.
The central bank aims to increase the effect of money multiplier. By lowering the reserve requirement ratio, banks are effectively encouraged to lend. China can thus create money supply through credit expansion and utilise the existing level of the monetary base more efficiently.
"After today’s announcement in the RRR cut, we expect a further cut in January 2019. As we previously forecast in our insight note, the PBoC has started to normalise policy and they will continue to lower the RRR," ANZ Research commented in its report.


U.S.-India Trade Framework Signals Major Shift in Tariffs, Energy, and Supply Chains
BOJ Rate Decision in Focus as Yen Weakness and Inflation Shape Market Outlook
Fed Governor Lisa Cook Warns Inflation Risks Remain as Rates Stay Steady
Trump Signs Executive Order Threatening 25% Tariffs on Countries Trading With Iran
South Korea’s Weak Won Struggles as Retail Investors Pour Money Into U.S. Stocks
Gold Prices Slide Below $5,000 as Strong Dollar and Central Bank Outlook Weigh on Metals
Trump’s Inflation Claims Clash With Voters’ Cost-of-Living Reality
Gold and Silver Prices Slide as Dollar Strength and Easing Tensions Weigh on Metals
MAS Holds Monetary Policy Steady as Strong Growth Raises Inflation Risks
Gold Prices Fall Amid Rate Jitters; Copper Steady as China Stimulus Eyed
Japanese Pharmaceutical Stocks Slide as TrumpRx.gov Launch Sparks Market Concerns 



